The FDA approval makes ocrelizumab a new treatment option for children aged 10 years and older with relapsing-remitting multiple sclerosis.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-approves-ocrelizumab-pediatric-relapsing-ms-2026a1000f5m?src=rss
Author :
Publish date : 2026-05-11 19:07:00
Copyright for syndicated content belongs to the linked Source.